News

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its…

10 months ago

Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board

Dijon, FRANCE, February 12, 2025 – 0730 (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company…

10 months ago

Meet Kayo 1G Live Resin Disposable – The Hemp Doctor’s Newest Heavy Hitter

MOORESVILLE, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, a trusted name in delivering premium hemp-derived products in…

10 months ago

ÂMÉ Expands to Dubai to Reach Middle Eastern Market

Photo credit: Jen Alsehali DUBAI, United Arab Emirates, Feb. 11, 2025 (GLOBE NEWSWIRE) -- ÂMÉ, a leading luxury skincare brand…

10 months ago

UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 

GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension Saqib Islam, SpringWorks Therapeutics…

10 months ago

Lighthouse Autism Center Announces Expansion of ABA Services in Nebraska 

Leading ABA Provider Set to Open Newest Location in Lincoln, NE. Therapy Room at LAC Therapy Room at LAC Therapy…

10 months ago

Microbot Medical Closes $13 Million Registered Direct Offering

BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously…

10 months ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative…

10 months ago

SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 

GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension Saqib Islam, SpringWorks Therapeutics…

10 months ago

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing…

10 months ago